J&J drops Phase III MDD programme due to lack of efficacy
J&J's news about aticaprant's Phase III programme comes two months after Neumora’s MDD drug also failed in a Phase III trial.
J&J's news about aticaprant's Phase III programme comes two months after Neumora’s MDD drug also failed in a Phase III trial.
What's Your Reaction?
